{"id":"dalfampridine-pill","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dalfampridine is a potassium channel blocker that increases the conduction velocity in the central nervous system, which is beneficial for patients with multiple sclerosis.","oneSentence":"Blocks potassium channels to enhance nerve conduction","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:03.624Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT02868567","phase":"PHASE1","title":"Use of Dalfampridine in Primary Lateral Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2016-03","conditions":"Motor Neuron Disease, Upper","enrollment":35},{"nctId":"NCT01645787","phase":"PHASE2, PHASE3","title":"Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-06-01","conditions":"Spinal Muscular Atrophy","enrollment":11},{"nctId":"NCT05859802","phase":"PHASE2, PHASE3","title":"Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis","status":"COMPLETED","sponsor":"D'Youville College","startDate":"2011-07-13","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT04026568","phase":"PHASE2, PHASE3","title":"A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-08-17","conditions":"Nerve Injury","enrollment":1},{"nctId":"NCT01337986","phase":"PHASE2, PHASE3","title":"Ampyra for Optic Neuritis in Multiple Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-05","conditions":"Multiple Sclerosis, Optic Neuritis","enrollment":53},{"nctId":"NCT02146534","phase":"PHASE4","title":"Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients","status":"COMPLETED","sponsor":"Clinique Neuro-Outaouais","startDate":"2013-12","conditions":"Multiple Sclerosis","enrollment":44},{"nctId":"NCT03658408","phase":"PHASE2","title":"4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy","status":"WITHDRAWN","sponsor":"University of Rochester","startDate":"2018-10-03","conditions":"Prostate Disease","enrollment":""},{"nctId":"NCT01356940","phase":"PHASE4","title":"A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis","status":"COMPLETED","sponsor":"Brown, Theodore R., M.D., MPH","startDate":"2010-11","conditions":"Multiple Sclerosis","enrollment":43},{"nctId":"NCT00127530","phase":"PHASE3","title":"Study of Oral Fampridine-SR in Multiple Sclerosis","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2005-05","conditions":"Multiple Sclerosis","enrollment":300},{"nctId":"NCT02166346","phase":"PHASE2","title":"Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-02","conditions":"Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis","enrollment":24},{"nctId":"NCT00483652","phase":"PHASE3","title":"Study of Fampridine-SR Tablets in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2007-05","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT01975324","phase":"PHASE4","title":"A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)","status":"COMPLETED","sponsor":"Neuro-Ophthalmologic Associates, PC","startDate":"2013-07","conditions":"Non Arteritic Ischemic Optic Neuropathy","enrollment":20},{"nctId":"NCT01811706","phase":"NA","title":"Dalfampridine and Gait in Spinocerebellar Ataxias","status":"COMPLETED","sponsor":"University of Florida","startDate":"2013-02","conditions":"Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3","enrollment":20},{"nctId":"NCT01444300","phase":"PHASE2","title":"Dalfampridine for Imbalance in Multiple Sclerosis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2011-09","conditions":"Multiple Sclerosis, Fatigue","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Physical Therapy"],"phase":"phase_2","status":"active","brandName":"Dalfampridine Pill","genericName":"Dalfampridine Pill","companyName":"D'Youville College","companyId":"d-youville-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks potassium channels to enhance nerve conduction Used for Multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}